Kezar Life Sciences Stock News

Geode Capital Management LLC increased its position in shares of Kezar Life Sciences, Inc. (NASDAQ:KZR) by 11.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 573,459 shares of the companys stock after buying an additional 61,125 shares during the period. Geode Capital Management []

FinancialBuzz.coms latest The Buzz Show: Featuring Our Corporate News Recap on Kezar Life Sciences Inc. Announces Interim Results from the MISSION Phase 2 Trial Kezar Life Sciences Inc. (NASDAQ: KZR) surged over 42% in premarket trading after the company reported interim results from the Phase 2 portion of its MISSION clinical trial evaluating KZR-616. The The post The Buzz Show: Kezar Life Sciences Inc. (NASDAQ: KZR) MISSION Phase 2 Trial first appeared on Financial Buzz .

The company reported promising results from a phase 2 study.

The stock price of Kezar Life Sciences Inc (NASDAQ: KZR) increased by over 55% pre-market today. This is why it happened.

Kezar Life Sciences, Inc. (NASDAQ: KZR) shares are soaring Tuesday following a positive clinical readout. What Happened: California-based Kezar announced positive interim results from the Phase 2

KZR-616 demonstrates clinically meaningful benefit in patients with lupus nephritis, with 4 out of 5 patients achieving either a partial or complete renal response at end of treatment KZR-616 maintained a favorable safety and tolerability profile over the six-month treatment period Company-hosted investor and analyst conference call and webcast with guest investigator to be held today at 4:30pm ET SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported interim results from the Phase 2 portion of its MISSION clinical trial evaluating KZR-616, a first-in-class selective immunoproteasome inhibitor, in patients with active, proliferative lupus nephritis (LN). The MISSION Phase 2 interim results present a strong signal that KZR-616 is active and could be a meaningful therapy for patients with lupus nephritis, a long term and difficult to treat disease, said Noreen R.

Zacks Investment Research downgraded shares of Kezar Life Sciences (NASDAQ:KZR) from a hold rating to a sell rating in a research report report published on Saturday, Zacks.com reports. According to Zacks, Kezar Life Sciences, Inc. is a bio-technology company. It discovers and develops molecule therapeutics and medicines such as protein homeostasis for autoimmune disorders. The []

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated an

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and